What You Should Know:
- Today, the AI-powered genetic testing and precision medicine company Tempus announced that it has signed a significant strategic agreement with Pfizer to more precisely gather insights that will inform novel drug discovery and development in oncology.
- Through this collaboration, Pfizer has access to Tempus’ AI-enabled platform and its library of de-identified, multimodal data to uncover insights that will power therapeutic development in oncology.
-
Read More
Life Sciences | News, Analysis, Insights - HIT Consultant
Stratasys, Ricoh Partner to Provide On-Demand 3D-Printed Anatomic Models for Hospitals and Clinics
What You Should Know:
- Stratasys Ltd. today announced they have signed another agreement with RICOH USA to provide on-demand 3D-printed anatomic models for clinical settings.
- The demand for additive manufacturing within the healthcare industry is continuously growing, and according to Grandview Research, the global healthcare additive manufacturing market size was valued at USD 1.6 billion in 2021 and is expected to expand at a compound annual growth rate of 22.6% from 2022 to 2030.
Read More
What Impact Could AI Have On Genetic Testing?
The sequencing and analysis of human DNA have advanced significantly since the initial draft of a human genome that was published as part of the Human Genome Project. With DNA sequencing becoming increasingly cost-effective, the market for genetic testing is growing at an accelerating rate – the market for Next Generation Sequencing (NGS) services has an estimated annual growth of 18.3% from 2022 to 2030. AI presents a range of possibilities for this rapidly growing field, and in this article,
Read More
ObvioHealth Launches Digital Therapeutics API for Clinical Trials
What You Should Know:
- ObvioHealth launches proprietary application programming interface (API) tailored specifically for digital therapeutics (DTx) clinical trials.
- ObvioHealth’s API ensures tight integration between the digital therapeutic and the ObvioGo platform, providing sponsors with accurate data to correlate efficacy with adherence to the DTx. In addition, ObvioGo’s integration reduces participant task duplication because—in most cases—outcomes can be passively captured
Read More
Addressing the Diversity Challenge in Clinical Research Through Patient Advocacy
Diversity is paramount to the success of clinical research, both ethically and scientifically. Without adequate representation of racial and ethnic minorities, investigators lack an understanding of the safety and efficacy of novel treatments within those groups. From a scientific standpoint, an incomplete dataset hinders drug delivery and the development of breakthrough therapies – but from an ethical standpoint, underrepresentation creates a barrier to treatment options for populations that
Read More
Indegene Launches Metaverse Capabilities for Life Sciences Companies
What You Should Know:
- Indegene, a digital-first, life sciences commercialization company launches metaverse capabilities to support life sciences organizations with a variety of use cases, including health care provider (HCP) interactions, HCP education, and patient education.
- Indegene’s domain expertise will provide life sciences organizations a foundation for navigating the complexity of this emerging technology and the flexibility to create tailored virtual worlds. Using these, life
Read More
Vysioneer & Pfizer Partner on AI-Powered Oncology Clinical Trials
What You Should Know:
- Vysioneer, a provider of applied AI for Oncology, today announced a data-sharing agreement with Pfizer, a global leader in pharmaceuticals. The agreement aims to lay the foundation for the application of AI in oncology clinical trials.
As part of the agreement, Vysioneer gains access to one of Pfizer's oncology clinical trial datasets to apply Vysioneer's advanced machine-learning techniques to facilitate the drug efficacy assessment process, thereby allowing Pfizer
Read More
5 Components of a Patient-Centric eCOA Strategy for Oncology Clinical Trials
In the US alone, an estimated 1.9 million new cases of cancer were diagnosed in 2022, positioning oncology as a key subject of clinical research. Throughout oncology trial development, it is important that stakeholders acknowledge that only patients can fully understand the impact of treatment on their lives. Regulators are now looking beyond clinical indications such as tumor size and delayed disease progression. When evaluating the risks and benefits of treatment, they want to know whether the
Read More
Report: Pharma R&D ROI Falls to Lowest Level in 13 Years
What You Should Know:
- Deloitte Centre for Health Solutions releases its thirteenth annual report, ‘Seize the Digital Momentum: Measuring the return from pharmaceutical innovation 2022’ that explores the performance of the biopharmaceutical industry (bio Pharma) and its ability to generate returns from investment in innovative new medicines.
- Since 2021, much of the world has successfully adjusted to life where COVID-19 is more endemic as vaccines and treatments reduced the risk and
Read More
BenchSci Launches ‘Map’ of Biology Research Platform for Pharmaceutical Research
What You Should Know:
- BenchSci, a Canadian-based tech company and leader in AI solutions for drug discovery recently launches a Google-backed 'map' of biology research platform, ASCEND™ by BenchSci, to understand the underlying biology.
- The patented machine learning platform reads millions of published and previously hidden experiment external and internal data sources to create a map that allows scientists to more quickly (50% more) and accurately understand the biological
Read More
